Orodispersible Tablets Market is Estimated to Witness High Growth Owing to Opportunity in Pediatric and Geriatric Population

Orodispersible tablets are convenient dosage forms which rapidly disintegrate or dissolve in the saliva without chewing or the need for water. They offer fast onset of action, better patient compliance especially for pediatric and geriatric patients who have difficulty in swallowing conventional tablets and capsules. The global Orodispersible Tablets Market is estimated to be valued at US$ 4.9 Bn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
The potential opportunity in pediatric and geriatric population is estimated to drive the growth of orodispersible tablets market during the forecast period. Currently, over 900 million people worldwide are above the age of 60 years and this segment is rising at a rate of about 3% per year. As the swallowing difficulties tend to increase with age, orodispersible tablets offer a suitable alternative to conventional dosage forms for the geriatric population. Similarly, pediatric patients find it difficult to swallow large sized tablets and capsules. Orodispersible tablets dissolve rapidly in saliva, eliminating the need for water and are considered a preferred dosage form for pediatric patients. Hence, the growing pediatric and geriatric population worldwide suggests immense opportunity for the players in orodispersible tablets market.

Porter’s Analysis
Threat of new entrants: Low economies of scale and barriers in manufacturing orodispersible tablets makes the threat of new entrants moderate.

Bargaining power of buyers: Large number of buyers and manufactures provide buyers with good options and bargaining power.

Bargaining power of suppliers: Few suppliers for required excipients gives them strong bargaining power.

Threat of new substitutes: Substitutes like conventional tablets and liquid formulations pose moderate threat.

Competitive rivalry: Fierce competition among existing players drives continued innovation.

SWOT Analysis
Strengths: High patient compliance for those unable to swallow tablets. Offers convenience as tablets disperse rapidly.

Weaknesses: More expensive than conventional tablet forms.Requires specialized manufacturing process and equipment.

Opportunities: Growing aging population and increased focus on patient centricity is increasing demand. Emerging economies provide new growth avenues.

Threats: stringent regulations and potential quality issues during manufacturing or storage. Intense pricing pressure from large players.

Key Takeaways
The global orodispersible tablets market is expected to witness high growth.

North America currently dominates the market due to high healthcare spending and early adoption of new drug delivery technologies. However, Asia Pacific is expected to grow at the fastest pace owing to increasing generic drug production in countries like India and China serving both domestic and international markets.

Key players operating in the orodispersible tablets market are Alnylam Pharmaceuticals, IntelGenx, Pfizer, Nova Laboratories, Biogen, Merck, Bayer, GSK, and Morepen Laboratories. Manufacturers are focusing on expanding to emerging markets and introducing innovative formulation technologies to drive faster dispersion. They are also investing in enhancing production capacities and capabilities for specialized orally disintegrating excipients.